LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

LLY

775.15

-2.1%↓

JNJ

152.39

+0.45%↑

ABBV

184.42

-0.99%↓

NVO

68.11

+0.95%↑

UNH

306.72

+1.67%↑

Search

Haemonetics Corp

Aperta

SettoreSettore sanitario

73.69 -0.42

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

73.23

Massimo

75.13

Metriche Chiave

By Trading Economics

Entrata

20M

58M

Vendite

-18M

331M

P/E

Media del settore

21.773

50.291

EPS

1.24

Margine di Profitto

17.538

Dipendenti

3,023

EBITDA

-19M

71M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+19.79% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

285M

3.5B

Apertura precedente

74.11

Chiusura precedente

73.69

Notizie sul Sentiment di mercato

By Acuity

8%

92%

4 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Haemonetics Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 giu 2025, 23:49 UTC

Utili

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 giu 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 giu 2025, 21:30 UTC

Utili

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 giu 2025, 21:07 UTC

Utili

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 giu 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 giu 2025, 23:39 UTC

Discorsi di Mercato

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 giu 2025, 23:34 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 giu 2025, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 giu 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 giu 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 giu 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 giu 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 giu 2025, 23:30 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 giu 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 giu 2025, 23:19 UTC

Acquisizioni, Fusioni, Takeovers

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 giu 2025, 22:06 UTC

Utili

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 giu 2025, 21:15 UTC

Utili

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 giu 2025, 21:07 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 giu 2025, 21:07 UTC

Utili

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 giu 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 giu 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 giu 2025, 21:06 UTC

Discorsi di Mercato

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 giu 2025, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 giu 2025, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 giu 2025, 20:52 UTC

Utili

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 giu 2025, 20:51 UTC

Utili

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 giu 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

26 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Haemonetics Corp Previsione

Obiettivo di Prezzo

By TipRanks

19.79% in crescita

Previsioni per 12 mesi

Media 89.57 USD  19.79%

Alto 105 USD

Basso 71 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Haemonetics Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

6

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

62.51 / N/ASupporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

4 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.